FRONTEO, Inc. (headquarter: Minato-ku, Tokyo, CEO: Masahiro Morimoto) has launched a new AI drug discovery support service, using FRONTEO's in-house developed AI engine in the AI drug discovery support business "Drug Discovery AI Factory (DDAIF)" and analyzing data from across 600 journals published by Springer Nature (headquarter: Berlin, Germany, CEO: Frank Vrancken Peeters).
This service will analyze articles published across 600 journals in Springer Nature’s portfolio including, Nature, Nature Medicine, Nature Reviews Drug Discovery, Cell Death & Differentiation. By using full-text data from cutting-edge papers for analysis, it is expected that the volume of information will significantly increase and the speed and quality of reaching the desired information will improve. This new approach will enable to capture a greater number of genes and target molecules earlier than ever before, and to propose novel target molecules, indications, and these hypotheses to the clients in DDAIF.
DDAIF is a service that supports the efficiency, acceleration, and improvement of success probability of drug discovery by utilizing FRONTEO's in-house developed AI specialized in hypothesis generation for drug R&D. Hypotheses in drug research and development predict mechanisms based on the relationship between a target molecule and a disease. This plays an extremely important role in the various phases of development, from target discovery, which is the most upstream stage of development, to clinical trials and commercial launch. DDAIF generates and proposes evidence-based hypotheses to meet the needs of the clients, including the search and evaluation of highly novel target molecules and biomarkers, mechanism elucidation, indication proposals, and seed evaluation.
FRONTEO will continue to expand its DDAIF services to meet the needs of pharmaceutical companies and other customers.
■ About FRONTEO URL: https://www.fronteo.com/
FRONTEO, Inc. is a data analysis company that provides various AI solutions and services using the in-house developed AI engine "KIBIT".
Based on the philosophy of "realizing fairness in the information society by providing solutions that do not overlook risks and opportunities buried in records", FRONTEO’s strengths lie in natural language processing and network analysis technologies that extract meaningful and important information from vast amounts of text data and complex networks to support advanced decision-making by experts.
Developing businesses in the areas of LegalTech AI, Business Intelligence, Life Science AI, and Economic Security. Contributing to solving various corporate and social issues. Established in August 2003, listed on Tokyo Stock Exchange Mothers (currently TSE Growth) on June 26, 2007. Offices are located in Japan, USA, South Korea and Taiwan. Obtained a first-class medical device manufacturing and sales business license, registered controlled medical device sales business. The capital is 3,042,317 thousand yen (as of March 31, 2023).
FRONTEO, KIBIT and Drug Discovery AI Factory are registered trademarks of FRONTEO in Japan.